Abstract Recurrent Sclerosing Basal-Cell Carcinoma. Presented by Dr. Floyd J. Dornbush. This 68-year-old white woman was first seen by me in 1953 because of a lesion on the left temple. At that time she stated that she had had a skin cancer which was treated with four x-ray treatments approximately six years previously. After these x-ray treatments, the entire lesion was excised. The wound never healed completely. When first seen she presented a 2 in. long, linear scar, overlying the left eye with a central ulcer, 5×8 mm. in diameter. It was felt that this represented a recurrent basal-cell carcinoma. At that time, it was thoroughly curetted and desiccated in the Los Angeles County General Hospital. The lesion healed but did not remain free of disease. Six to eight months later, it began to scale and ulcerate again. At that time, the entire scar was excised in an
A.M.A. Archives of Dermatology – American Medical Association
Published: Jul 1, 1959
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera